Claim: Pfizer pulls Lipitor ads with heart expert Jarvik.
Verdict: SUPPORTS

Retrieved passages:
title: Robert Jarvik
text: Jarvik, along with DeVries, briefed the world’s media on Clark’s condition. The next several implantations of the Jarvik-7 heart were conducted by Humana, a large health care insurance company. The second patient, William J. Schroeder, survived 620 days. In 2006, Jarvik began appearing in television commercials for Pfizer's cholesterol medication Lipitor. Two members of Congress, as part of their campaign against celebrity endorsements, began an investigation as to whether his television advertisements constitute medical advice given without a license to practice medicine. One advert depicted Jarvik rowing, but due to insurance and other considerations, he did not row himself, and

title: Robert Jarvik
text: a body double was used. Later, Jarvik said that he had not taken Lipitor until becoming a spokesman for the company. On February 25, 2008, Pfizer announced that it would discontinue its ads with Jarvik. Jarvik is married to "Parade" magazine columnist Marilyn vos Savant since August 23, 1987. Contrary to some sources, Jarvik is not a Latter-day Saint. Robert Jarvik Robert Koffler Jarvik, M.D. (born May 11, 1946) is an American scientist, researcher, and entrepreneur known for his role in developing the Jarvik-7 artificial heart. Robert Jarvik was born in Midland, Michigan, to Norman Eugene Jarvik and Edythe Koffler

title: Atorvastatin
text: into a co-marketing agreement with Pfizer to sell Lipitor, and in 2000 Pfizer acquired Warner-Lambert for $90.2billion. Lipitor was on the market by 1996. By 2003 Lipitor had become the best selling pharmaceutical in the United States. From 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125billion in sales over approximately 14.5years. Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years." Pfizer's patent on atorvastatin expired in November 2011. Atorvastatin calcium tablets are marketed by Pfizer under the trade name Lipitor for oral

title: Pfizer
text: Angiosyn for $527 million. On June 26, 2006, Pfizer announced it would sell its Consumer Healthcare unit (manufacturer of Listerine, Nicorette, Visine, Sudafed and Neosporin) to Johnson & Johnson for $16.6 billion. Development of torcetrapib, a drug that increases production of HDL, or "good cholesterol", which reduces LDL thought to be correlated to heart disease, was cancelled in December 2006. During a Phase III clinical trial involving 15,000 patients, more deaths occurred in the group that took the medicine than expected, and a sixty percent increase in mortality was seen among patients taking the combination of torcetrapib and Lipitor versus

title: Robert Jarvik
text: Robert Jarvik Robert Koffler Jarvik, M.D. (born May 11, 1946) is an American scientist, researcher, and entrepreneur known for his role in developing the Jarvik-7 artificial heart. Robert Jarvik was born in Midland, Michigan, to Norman Eugene Jarvik and Edythe Koffler Jarvik, and raised in Stamford, Connecticut. He is the nephew of Murray Jarvik, a pharmacologist who was the co-inventor of the nicotine patch. Jarvik is a graduate of Syracuse University. He earned a master's degree in medical engineering from New York University. After being admitted to the University of Utah School of Medicine, Jarvik completed two years of study,

title: Pfizer
text: company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug. In 2016, Pfizer Inc. was expected to merge with Allergan, Plc to create the Ireland-based "Pfizer plc" in a deal that would have been worth $160 billion. The merger was called off in April 2016,

title: Atorvastatin
text: administration. Tablets are white, elliptical, and film-coated. Pfizer also packages the medication in combination with other medications, such as with amlodipine (brand name Caduet). Pfizer recommends that patients do not break tablets in half to take half-doses, even when this is recommended by their doctors. Pfizer's US patent on Lipitor expired on 30 November 2011. Initially, generic atorvastatin was manufactured only by Watson Pharmaceuticals and India's Ranbaxy Laboratories. Prices for the generic version did not drop to the level of other generics—$10 or less for a month's supply—until other manufacturers began to supply the medication in May 2012. In other

title: Dr. Reddy's Laboratories
text: Pfizer as Lipitor, an anti-cholesterol medication. Reddy's was already linked to UK pharmaceuticals multinational Glaxo Smithkline. Dr. Reddy's originally launched in 1984 producing active pharmaceutical ingredients. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognized brand in India. Soon, Dr. Reddy's obtained another success with Omez, its branded omeprazole – ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time. This is now branched in hyderabad Within a year, Reddy's became the first Indian company to export the active

title: Ian Read
text: a member of the Pfizer Leadership Team. On 5 December 2010, When Read "took over from Jeffrey Kindler as Pfizer’s CEO, the drug firm–the world’s largest–was facing the impending patent expiration of Lipitor, the bestselling drug ever made, and the utter failure of one of the most lavishly funded research laboratories on the planet to develop much of anything." Read is also a director of Kimberly-Clark. Read is now an American citizen. By October 2015 during the Drug Pricing Firestorm, Forbes journalist Matthew Herper, wrote how "Read, with his calculating mind, must get through the public’s rage over six-figure price

title: Pfizer
text: Lipitor alone. Lipitor alone was not implicated in the results, but Pfizer lost nearly $1 billion developing the failed drug and the market value of the company plummeted afterwards. The company also announced it would acquire Powermed and Rivax. In September 2009, Pfizer pleaded guilty to the illegal marketing of the arthritis drug Bextra for uses unapproved by the U.S. Food and Drug Administration (FDA), and agreed to a $2.3 billion settlement, the largest health care fraud settlement at that time. A July 2010 article in "BusinessWeek" reported that Pfizer was seeing more success in its battle against makers of

title: Apotex
text: Farmaceutica to extend the company's presence in Western Europe. In 2010, Apotex launched a generic version of Pfizer Inc.'s cholesterol-lowering Lipitor drug in Canada, after four years of patent litigation with Pfizer. Apotex's generic version was launched under the name of Apo-Atorvastatin. This saved provincial health programs over $800 million per year. In 2010, Apotex was listed in the eighth position in a report published by FiercePharma listing the top U.S. generic companies, based on sales from January 2009 to December 2009. In 2012, Apotex launched a generic version of Crestor, the cardiovascular drug originally patented and manufactured by AstraZeneca.

title: Steven Nissen
text: RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug. In 2003 Nissen led a "Journal of the American Medical Association" study, producing evidence that five weekly infusions of ApoA-I Milano/phospholipids complex, a synthetic form of HDL, can possibly remove significant amounts of plaque from coronary arteries. The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for

title: Esperion Therapeutics
text: co-discovered the statin marketed as Lipitor® — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company. In June 2013, Esperion became a public company again through an initial public offering. , Esperion was traded on NASDAQ under the symbol "ESPR". ETC-1002 is an innovative, first-in-class, orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering

title: Ranbaxy Laboratories
text: Europe: 17%, Brazil, Russia, and China: 29%). In December 2005, Ranbaxy's share price was hit by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion. In June 2008, Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium, the generic version of Lipitor and Atorvastatin Calcium-Amylodipine Besylate, the generic version of Pfizer's Caduet in US starting on 30 November 2011. On 23 June 2006, Ranbaxy received from United States Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in US

title: Bruce Roth
text: inventor of "trans"-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one, patented in 1986, and developed into the on-market drug, atorvastatin, which ultimately would be sold as Lipitor, and which would become the largest-selling drug in pharmaceutical history by 2003. Pfizer acquired Warner-Lambert and Lipitor in 2000. From 1996 until 2007, Roth served as an adjunct professor in the Department of Medicinal Chemistry at the University of Michigan. For the discovery of atorvastatin, Roth received the 1997 Warner-Lambert Chairman's Distinguished Scientific Achievement Award, the 1999 Inventor of the Year Award from the New York Intellectual Property Law Association, the 2003 American Chemical Society Award for

title: Steven Nissen
text: $1.3 billion. Also in 2005, Nissen published the results of the REVERSAL trial, a headto-head comparison of the statins atorvastatin (Lipitor) and pravastatin (Pravachol). IVUS images showed that Lipitor had effectively halted the progression of plaque buildup, but coronary disease progressed considerably in those given Pravachol. The study suggested that treatments should aim to lower LDL, or “bad” cholesterol levels as much as possible. In 2006, Nissen and his co-investigators reported on The ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden). The study concluded that intensive use of statins resulting in a

title: Statin
text: HMG-CoA reductase which plays a central role in the production of cholesterol. High cholesterol levels have been associated with cardiovascular disease. , a number of statins are on the market: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Several combination preparations of a statin and another agent, such as ezetimibe/simvastatin, are also available. In 2005, sales were estimated at US$18.7billion in the United States. The best-selling statin is atorvastatin also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. The manufacturer Pfizer reported sales of US$12.4billion in 2008. Due to patent expirations, several statins became available in

title: Bruce Roth
text: Bruce Roth Bruce D. Roth (born June 1954) is an American organic and medicinal chemist that trained at Iowa State University and the University of Rochester, who, at the age of 32, discovered atorvastatin, the statin-class drug sold as Lipitor that would become the largest-selling drug in pharmaceutical history (as of 2003). His honours include being named a 2008 Hero of Chemistry by the American Chemical Society, and being chosen as the Perkin Medal awardee, the highest honour given in the U.S. chemical industry, by the Society of Chemical Industry, American section in 2013. Roth was born in June 1954.

title: Warner–Lambert
text: which was founded in Detroit in 1866, by Hervey Parke and George Davis. This was followed by acquisitions of Wilkinson Sword in March 1993, and Agouron Pharmaceuticals in January 1999. Its subsidiary Parke-Davis marketed the antidiabetic drug Rezulin, which had FDA approval from January 1997 to 2000. In the end of the 1990s, Warner–Lambert formed an alliance with Pfizer to bring its drug, Lipitor, to market. Lipitor launched in January 1997 to resounding success, reaching $1B in domestic sales within its first twelve months on the market. In February 2000, Pfizer bought Warner Lambert along with all of its subsidiary

title: Ezetimibe/atorvastatin
text: studying the endpoints of heart attacks, strokes and heart-related deaths is scheduled to conclude in 2014. Liptruzet was withdrawn from sale by its manufacturer in June 2015 but not for reasons of safety or effectiveness. This combination drug works to reduce cholesterol levels through two different pathways. The ezetimibe component of the medication works by inhibiting cholesterol absorption from food while the atorvastatin component inhibits intrinsic cholesterol production in the liver. Ezetimibe/atorvastatin Ezetimibe/atorvastatin (brand name Liptruzet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013 by the Food and Drug Administration for the